CCL2 and fatty liver disease: Blocking the IKK ɛ and TBK1 pathways can significantly reduce the inflammatory factors produced by pro-inflammatory cells such as TNF- α and MCP-1, thereby improving insulin sensitivity and reducing liver steatosis (Reilly et al., 2013).